Table 1 Baseline characteristics of study cohort

Number of patients

(% of all patients)

107/266 (40.2%)

87/266 (32.7%)

4/266 (1.5%)

30/266 (11.3%)

13/266 (4.9%)

10/266 (3.8%)

15/266 (5.6%)

Number of girls

(% within category)

82/107 (76.6%)

70/87 (80.4%)

3/4 (75%)

8/30 (26.6%)

9/13 (69.2%)

4/10 (40.0%)

10/15 (66.6%)

Age in years at diagnosis, median (range)

5.0 (0.5–15.6)

6.1 (1.0–16.2)

10.9 (8.5–12.0)

10.8 (1.4–16.1)

10.2 (1.4–15.7)

5.9 (0.9–13.4)

8.1 (3.0–14.6)

Duration of symptoms in months, median (range)

8.2 (0.0–57.1)

10.4 (0.6–139.6)

6.5 (1.0–9.7)

12.5 (1.2–70.1)

7.8 (2.2–14.0)

5.2 (1.4–10.7)

10.1 (0.4–31.2)

Duration between diagnosis and enrollment in days, median (range)

42 (0–327)

28 (0–363)

110 (1–142)

76 (0–363)

62 (6–232)

72 (7–327)

42 (3–261)

cJADAS-10, median (range)

8.45 (2–18.5)

13.7 (1.5–27)

8.62 (4–14.5)

10.45 (2.5–22)

14.3 (4–23.5)

14.25 (2–24.5)

11.5 (1.5–22.5)

Active joint count, median (range)

1.8 (0–7)*

9.9 (0–57)

3 (2–5)

3.6 (0–16)

8.2 (0–29)

11.4 (0–57)

5.9 (1–31)

CRP in mg/l, median (range)

6.53 (0–100)

10.8 (0–124)

0.57 (0–1.1)

9.56 (0–65)

4.8 (0–15)

47.87 (4.7–96.8)

17.2 (0–53)

 Synthetic DMARDs

54/107 (50.5%)

65/87 (74.7%)

3/4 (75%)

14/30 (46.7%)

8/13 (61.5%)

7/10 (70%)

5/15 (33.3%)

 Systemic glucocorticoids, current

19/107 (17.8%)

41/87 (47.1%)

1/4 (25%)

6/30 (20%)

7/13 (53.8%)

10/10 (100%)

3/15 (20%)

 Systemic glucocorticoids, last 6 months before baseline

20/107 (18.7%)

27/87 (31.03%)

1/4 (25%)

7/30 (23.4%)

6/13 (46.1%)

7/10 (70%)

4/15 (26.7%)

 Intraarticular glucocorticoids, last 6 months before baseline

62/107 (57.9%)

47/87 (54.02%)

1/4 (25%)

8/30 (26.7%)

3/13 (23.1%)

3/10 (30%)

6/15 (40%)

 Biologic DMARDs

2/107 (1.9%)

ADA - 2

2/87 (2.3%)

ETN - 2

0 (0.0%)

3/30 (10%)

ETN - 3

1/13 (7.7%)

ETN - 1

3/10 (30.0%)

ANA – 1

CAN – 1

TCZ – 1

1/15 (6.7%)

ETN - 1

 Treatment naive

27/107 (25.2%)

7/87 (8.0%)

12/30 (40.0%)

3/13 (23.1%)

5/15 (33.3%)